Margetuximab Recruiting Phase 1 Trials for Advanced Solid Tumors / Neoplasms, Hematologic Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03219268A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms